Fu DJ, Keenan TD, Faes L, et al. - In this cohort study involving 7,802 patients (mean [SD] age, 78.7 [8.8] years; 4776 women [61.2%]; and 4785 White [61.3%]), researchers sought to explore the potential usefulness of survival analysis techniques for retrospective clinical practice visual outcomes. Between October 28, 2008, and February 1, 2020, 7,802 eyes out of 10,744 eyes with neovascular age-related macular degeneration receiving anti-vascular endothelial growth factor (VEGF) therapy met study criteria (treatment-naive, first-treated eyes starting anti-VEGF therapy). According to findings, patients starting anti-VEGF therapy with neovascular age-related macular degeneration were more likely to receive positive visual outcomes within the first 2.0 years after treatment, usually sustaining this outcome for 1.1 years, but then worsening within 8.7 years to impaired vision. The potential utility of the proposed analyses is illustrated by these results. In conjunction with the statistical approach for retrospective analysis, this data set can provide long-term prognostic information for newly diagnosed patients with this disorder.